Madison Clarke
There are several types of rabies vaccines available that are both safe and effective. The rabies vaccine was first introduced in 1885 by French scientists Louis Pasteur and Émile Roux, and since then, there have been numerous attempts to develop rabies vaccines to prevent rabies in both humans and animals. Today, two types of vaccines exist to protect against rabies in humans: nerve tissue and cell culture vaccines. While nerve tissue vaccines are still used in some countries, they are not as effective as the modern cell culture vaccines that were introduced in the early 1980s. The World Health Organization (WHO) recommends the discontinuation of nerve tissue vaccines and their replacement with cell culture vaccines, which are safer, more effective, and more affordable. Cell culture vaccines are also available for animals, and vaccinating dogs is very effective in preventing the spread of rabies to humans.
Rabies Vaccines Grown on Human Cell Culture
| Characteristics | Values |
|---|---|
| History | The rabies vaccine was first introduced in the early 1980s and cost $45 per dose. |
| Types | There are two types of rabies vaccines: nerve tissue and cell culture vaccines. |
| Cell Culture Vaccines | These are more affordable, efficacious, safer, and require less vaccine than nerve tissue vaccines. |
| Inactivated Vaccines | These are produced using various rabies virus strains and are inactivated using beta propiolactone (BPL), ultraviolet light, acetylethylamine, or binary ethylenimine (BEI). |
| Embryo Vaccines | Duck embryos are used as an alternative to chicken embryos in vaccine production. |
| Human Cell-Grown Vaccines | The US uses a split-product vaccine, while Europe uses whole-virion vaccines. |
| Doses | For pre-exposure, the vaccine is given in three 1-ml doses on days 0, 7, and 21. For post-exposure, a person should be given human rabies immune globulin followed by five intramuscular doses of the vaccine on days 0, 3, 7, 14, and 28. |
| Booster Doses | For long-term immunity, booster doses are given at two-year intervals. |
| Cost | In 2015, a course of three doses in the US could cost over $1,000, while in Europe, it costs around €100. |
| Alternatives | Intradermal vaccination is recommended by the WHO as an alternative to intramuscular vaccination as it is safe, effective, and cost-saving. |
| Prophylaxis | Pre-exposure prophylaxis is recommended for anyone at increased risk of exposure to the rabies virus. |
| Post-exposure Treatment | Post-exposure prophylaxis (PEP) includes wound treatment, administration of rabies vaccines, and rabies immunoglobulin if indicated. |
| Animal Vaccines | Vaccinating dogs is effective in preventing the spread of rabies to humans. |
| Successful Programs | The Philippines, Ecuador, Mexico, and Tunisia have implemented successful rabies control programs through dog vaccination. |
Explore related products
What You'll Learn
- The first rabies vaccination was developed in 1885
- Modern cell-culture rabies vaccines were introduced in the 1980s
- Vaccinating dogs is very effective in preventing the spread of rabies to humans
- Human cell-grown vaccines are a replacement for vaccines prepared in animal tissues
- The World Health Organization (WHO) recommends nerve tissue vaccines be replaced by modern cell culture vaccines
The first rabies vaccination was developed in 1885
Rabies is a terrifying virus, and before the development of a vaccine, almost all infections resulted in death. The first rabies vaccination was developed in 1885 by two French scientists, Louis Pasteur and Émile Roux. The first human to receive this vaccine was nine-year-old Joseph Meister, who had been bitten or mauled by a rabid dog and was at risk of dying.
Dr Jacques Joseph Grancher, who specialised in tuberculosis, convinced Pasteur to administer the vaccine to young Meister. On July 6, 1885, at 8 pm, Meister received the first injection, which was derived from the spinal cord of an inoculated rabbit that had died of rabies 15 days earlier. Over the next 10 days, 12 additional doses were administered, with later doses being progressively more virulent.
Pasteur and Roux's vaccine attenuated the harvested virus samples by allowing them to dry for five to ten days. This first rabies vaccine was a resounding success, saving Meister's life. The breakthrough had far-reaching implications, with patients with rabies coming from all over the world to receive the vaccine. This prompted the establishment of a dedicated vaccination centre near Pasteur's laboratory.
The success of the first rabies vaccine paved the way for further advancements. An improved version was introduced in 1908, and in the early 1980s, a modern cell-culture rabies vaccine was introduced. However, the cost of this vaccine, initially $45 per dose, was considered too expensive, limiting access for travellers from developed countries. Today, rabies vaccines are still recommended for those at high risk of exposure, and various safe and effective options are available.
Hepatitis B Vaccine: How Many Shots Needed?
You may want to see also
Explore related products
Modern cell-culture rabies vaccines were introduced in the 1980s
Rabies is a disease that has been causing fatalities for millennia, with the first interactions between humans and the virus likely occurring when humans first began domesticating dogs. As a result, rabies prevention strategies have been in development since the first century BC.
The first rabies vaccine was developed in 1885 by French scientists Louis Pasteur and Émile Roux. Nine-year-old Joseph Meister, who had been mauled by a rabid dog, was the first human to receive this vaccine. The treatment started with a subcutaneous injection derived from the spinal cord of an inoculated rabbit that had died of rabies. All the doses were obtained by attenuation, with later doses being progressively more virulent. Similar nerve tissue-derived vaccines are still used in some countries today, although they are not as effective as modern cell culture vaccines.
In 1979, the Van Houweling Research Laboratory of the Silliman University Medical Center in the Philippines developed and produced a dog vaccine that gave three years of immunity from rabies. This vaccine resulted in the elimination of rabies in many parts of the Visayas and Mindanao Islands. The successful program in the Philippines was later used as a model by other countries, such as Ecuador and the Mexican state of Yucatán, in their fight against rabies.
Today, there are several rabies vaccines available that are both safe and effective. Vaccinations must be administered prior to rabies virus exposure or within the latent period after exposure to prevent the disease. In many jurisdictions, domestic dogs, cats, ferrets, and rabbits are required to be vaccinated.
Bacterial Meningitis Vaccine: Who Should Avoid It?
You may want to see also
Explore related products
Vaccinating dogs is very effective in preventing the spread of rabies to humans
Rabies is a viral disease that is almost always fatal. The virus, RABV, is transmitted to humans through bites or scratches from infected animals, or even through indirect contact with the saliva of an infected animal. The rabies virus is most commonly found in bats, skunks, raccoons, and foxes, but dogs can also become infected and carry the virus. In developing countries, most people get rabies from domestic dogs.
The rabies vaccine was first introduced in 1885 by French scientists Louis Pasteur and Émile Roux. The first human to receive this vaccine was a nine-year-old boy named Joseph Meister, who had been mauled by a rabid dog. The vaccine has undergone improvements since its introduction, with a modern cell-culture rabies vaccine being introduced in the early 1980s. This modern vaccine is considered safe and effective for humans and animals, including dogs.
While human vaccination is important, it alone will not eliminate the disease, and costs will escalate over time. Thus, investing in eliminating the risk of rabies at its source, which is often dogs, is the most cost-effective measure. Vaccinating at least 70% of dogs in at-risk areas is now accepted as the most effective way to prevent human rabies deaths.
Vaccination Policy: A Collective Action Problem
You may want to see also
Explore related products
Human cell-grown vaccines are a replacement for vaccines prepared in animal tissues
Rabies vaccines prepared in human cell cultures are a replacement for the previously available vaccines that were prepared in animal tissues. These human cell-grown vaccines are more immunogenic and less reactogenic than their animal-tissue-based predecessors. The rabies vaccine is a life-saving preventive measure against the rabies virus, which has a nearly 100% fatality rate if left untreated.
The development of human cell-grown vaccines, including those for rabies, represents a significant advancement in vaccine development. Human cell strains used in vaccine development are typically descended from cells taken from fetuses, with the two main strains being WI-38 and MRC-5, both obtained in the 1960s. These cell lines have grown independently since their initial collection and have been used to develop several vaccines, including the rubella vaccine, which is now part of the combined MMR (measles, mumps, and rubella) vaccine.
Human cell-grown vaccines offer advantages over animal tissue-based vaccines in terms of immunogenicity and reactogenicity. In the case of rabies vaccines, the human cell-grown variety is a split-product vaccine in the United States, while those made in Europe are whole-virion vaccines. Both types of vaccines contain concentrated and inactivated "fixed" rabies virus. The human cell-grown rabies vaccine has been shown to provide long-term immunity, with booster doses recommended at two-year intervals for individuals continuously exposed to the risk of rabies.
The use of human cell cultures in vaccine development also addresses some of the limitations associated with animal-based vaccines. For example, the production of influenza vaccines in chicken eggs can be hindered by a reduced availability of eggs or by illnesses affecting egg-producing chickens. Human cell cultures do not face the same availability concerns and can help prevent potential vaccine shortages. Additionally, cell-based vaccines may be more effective than egg-based vaccines due to the risk of viral mutation during the long growth phase in chicken eggs, which can lead to a reduced effectiveness of the immune response.
While human cell-grown vaccines offer advantages, it is important to note that animal-based vaccines have also played a significant role in preventing diseases. For instance, nerve tissue-derived rabies vaccines, while less effective, are still used in some countries due to their lower cost compared to modern cell culture vaccines. Additionally, animal cell strains have been used to develop vaccines against Japanese encephalitis, rotavirus, polio, and smallpox. However, with advancements in technology and a better understanding of immunology, human cell-grown vaccines are becoming a preferred option due to their effectiveness, safety, and ability to address the limitations of animal-based vaccines.
How Antibody Production Can Be Stimulated
You may want to see also
Explore related products
The World Health Organization (WHO) recommends nerve tissue vaccines be replaced by modern cell culture vaccines
Rabies is a virus that is transmitted to humans through bites or scratches from an infected animal. The rabies virus can also be transmitted through indirect contact with saliva from an infected individual. The first rabies vaccine was introduced in 1885, and since then, several safe and effective rabies vaccines have been developed.
The World Health Organization (WHO) recommends that nerve tissue vaccines be replaced by modern cell culture vaccines. Nerve tissue vaccines, which are derived from animal tissues, are less effective and have greater side effects than cell culture vaccines. They also carry a risk of neurological complications. While nerve tissue vaccines are cheaper, cell culture vaccines are more efficacious and safer. In addition, cell culture vaccines are more affordable and require less vaccine, leading to lower direct costs.
The human diploid cell rabies vaccine (HDCV) was introduced in 1967. It is an inactivated vaccine made using the attenuated Pitman-Moore L503 strain of the virus. Newer purified chicken embryo cell vaccines (CCEEV) and purified Vero cell rabies vaccines are now available and recommended for use by the WHO. These vaccines can be used in both pre- and post-exposure vaccinations and are safe for humans and animals.
WHO recommends vaccinating individuals who are at high risk of contracting rabies, such as children living in endemic areas, veterinarians, researchers, and travelers to regions where rabies is common. Pre-exposure prophylaxis is recommended for anyone at increased risk of exposure to the rabies virus due to their residence or occupation. Post-exposure prophylaxis (PEP) includes wound treatment, the administration of rabies vaccines, and, if indicated, rabies immunoglobulin. Prompt administration of the rabies vaccine after exposure is critical to preventing the development of rabies before the virus reaches the brain.
Pneumonia Vaccine: What's Available in the US?
You may want to see also
Frequently asked questions
The rabies vaccine is used to prevent rabies, a disease that is transmitted to humans through bites or scratches from an infected animal.
There are two types of vaccines to protect against rabies in humans: nerve tissue and cell culture vaccines. Nerve tissue-derived vaccines are cheaper but less effective than modern cell culture vaccines.
No, not all rabies vaccines are grown on human cell culture. While human cell-grown vaccines are produced in the United States, vaccines made in Europe are whole-virion vaccines. Historically, nerve tissue vaccines were also used but are now being phased out due to their negative side effects.
Rabies vaccines are safe and effective in humans and other animals. Vaccinating dogs is a very effective way to prevent the spread of rabies to humans.
The cost of rabies vaccines varies depending on the region. In the United States, a course of three doses can cost over $1,000, while in Europe, a similar course costs around €100. The World Health Organization (WHO) recommends intradermal vaccination as an alternative to intramuscular vaccination as it is safe, effective, and more cost-saving.
